Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-082965
Filing Date
2024-07-11
Accepted
2024-07-11 16:11:22
Documents
81
Period of Report
2024-04-30

Document Format Files

Seq Description Document Type Size
1 10-K kalv-20240430.htm   iXBRL 10-K 2216445
2 EX-10.17# kalv-ex10_17.htm EX-10.17 169499
3 EX-21.1 kalv-ex21_1.htm EX-21.1 10186
4 EX-23.1 kalv-ex23_1.htm EX-23.1 3324
5 EX-31.1 kalv-ex31_1.htm EX-31.1 16591
6 EX-32.1 kalv-ex32_1.htm EX-32.1 6838
7 EX-97.1 kalv-ex97_1.htm EX-97.1 84822
  Complete submission text file 0000950170-24-082965.txt   8915582

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20240430.xsd EX-101.SCH 1171723
84 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20240430_htm.xml XML 1408166
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-K | Act: 34 | File No.: 001-36830 | Film No.: 241112170
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)